Corporate Presentation
ZEAL&
ZEALAND PHARMA
Forward-looking Statements
This presentation contains "forward-looking statements", as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as
amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma's expectations or forecasts of future events
regarding the research, development and commercialization of pharmaceutical products, the timing of the company's pre-clinical and clinical trials and the reporting
of data therefrom and the company's Significant events and potential catalysts in 2024 and Financial Guidance for 2024. These forward-looking statements may be
identified by words such as "aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential," "will," "would"
and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented.
The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate
assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to
be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events,
patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to
successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-
mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on
third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to effect the strategic reorganization
of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to
intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay
approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other
claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and
political uncertainty, including the ongoing military conflict in Ukraine and the uncertainty surrounding upcoming elections in the US.
If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by
such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking
statement. All such forward-looking statements speak only as of the date of this presentation and are based on information available to Zealand Pharma as of the
date of this presentation. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
2View entire presentation